Overview of Reguloid

Reguloid is a medicinal product classified as a bulk-forming laxative, a type of Gastrointestinal Therapy Agent, whose primary function is to promote natural bowel regularity and relieve occasional constipation through a physical mechanism. Its core active component is Psyllium Hydrophilic Mucilloid, which is a highly effective source of soluble fiber. The product is designed for oral administration and provides non-systemic relief by acting directly within the gastrointestinal tract.

Quick Facts	Description
Active ingredient	Psyllium Hydrophilic Mucilloid
Form	Oral Powder, Capsules, Granules
Pharmacological class	Bulk-forming Laxative
Common use	Occasional Constipation, Bowel Irregularity
Origin	Natural, Plant-based (Plantago ovata)

Is Reguloid a Drug or a Natural Fiber Supplement?

Reguloid’s composition establishes its identity as both a medicinal agent and a natural supplement. The essential active ingredient, Psyllium Hydrophilic Mucilloid, is a natural, plant-based substance derived from the seeds or husks of the Plantago ovata plant. This origin differentiates it from synthetic compounds. Psyllium is recognized for its ability to increase stool bulk and water content, as soluble fiber is vital for maintaining digestive health. Reguloid is available in diverse pharmaceutical preparations, including oral powder for suspension, capsules, and granules.

Reguloid's Classification and General Therapeutic Purpose

The product's classification as a bulk-forming laxative defines its specific therapeutic purpose, which is achieved through a localized physical action. The Psyllium fiber rapidly absorbs water when combined with liquid, forming a viscous, non-absorbed gel within the intestinal lumen. This process significantly increases stool bulk and its water content, which provides the necessary physical stimulus to encourage natural peristalsis. This action makes it effective for managing bowel irregularity and provides critical dietary fiber supplementation.

Regulatory References

What side effects are possible with Reguloid?

Possible Side Effects and Safety Information

The official safety profile for Reguloid (Psyllium Hydrophilic Mucilloid) is primarily structured around effects localized within the gastrointestinal tract, consistent with its classification as a bulk-forming laxative. The frequency and types of adverse reactions are documented by government regulatory agencies.

Adverse Reaction Scope

The most common adverse reactions are typically mild and localized:

Common Reactions: These include bloating, flatulence (gas), minor changes in bowel habits, and abdominal cramping or stomach pain. These effects are most often reported at the start of treatment and may lessen with continued use.
System Affected: Adverse effects are concentrated in the Gastrointestinal Disorders system, with occasional effects noted in the Immune System Disorders system (hypersensitivity).

Serious Safety Considerations and Constraints

The product label highlights the risk of serious adverse reactions, which are rare but critical, including esophageal obstruction, intestinal obstruction, or fecal impaction. These risks are strongly associated with inadequate fluid intake during administration.

Allergic Reactions: Hypersensitivity reactions, which can include severe symptoms like anaphylaxis (difficulty breathing, swelling of the face, throat, or tongue), are officially documented, requiring immediate caution.
Special Populations: The labeling includes notes for older adults, who may be at an increased risk of impaction or obstruction. As the active ingredient is not systemically absorbed, its safety profile is generally constrained to the local digestive action.
Safety Restriction: To prevent the product from decreasing the absorption of other medications, a time separation of at least two hours between taking Reguloid and other oral medicines is required. Reguloid is contraindicated in individuals with known intestinal obstruction or difficulty swallowing.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented information regarding Reguloid overdose, based strictly on government regulatory sources (e.g., FDA, EMA). No advice or clinical interpretation is provided.

Documented Overdose Manifestations

Overdose presentations are generally characterized by exaggerated pharmacological effects, primarily impacting the gastrointestinal system. Documented signs include abdominal pain, severe cramping, and persistent diarrhea and vomiting. Supratherapeutic doses pose a risk of serious complications, including severe dehydration and life-threatening electrolyte imbalance (e.g., low potassium levels).

Serious Outcomes and Emergency Action

Regulatory information specifies that complications such as profound hypotension (dangerously low blood pressure) and cardiac rhythm disturbances may occur secondary to severe fluid and electrolyte losses. Children are noted to be at a higher risk for rapid and severe dehydration compared to adults.

Immediate medical help is required for any suspected overdose. Government labeling explicitly instructs users to contact a Poison Control Center or seek emergency services right away in all cases of overdose, or if the user experiences severe symptoms such as passing out, difficulty breathing, or choking symptoms (chest pain, trouble swallowing) after taking the product.

Supportive Management

There is no specific pharmacologic antidote for Reguloid overdose. Management focuses on supportive care, which typically involves monitoring of vital signs, continuous cardiac observation, and administering intravenous fluids to correct dehydration and replace lost electrolytes.

Therapeutic Uses of Reguloid

Reguloid is commonly used across domains where additional symptomatic support is needed, applied in settings marked by temporary physiological imbalance. It generally helps address symptom clusters that may become disruptive and contributes to improved day-to-day comfort during symptomatic periods. Specifically, Reguloid is applied for managing the core symptoms of occasional constipation, bowel irregularity, and as an adjunct to diet for managing elevated cholesterol and post-meal blood sugar levels.

Relief for Constipation and Bowel Irregularity

Reguloid is used to help with symptoms related to physical discomfort, such as straining and infrequent defecation. It is relevant in conditions characterized by periods of heightened symptoms, including Chronic Idiopathic Constipation, or situations involving episodic manifestations. It supports the handling of distressing manifestations and contributes to easing the overall symptom load by easing the impact of straining.

Support for Stool Consistency and Metabolic Wellness

This product is relevant for easing symptom clusters that may become intense or fluctuate, particularly those linked to disordered stool consistency within the gastrointestinal tract and systemic imbalance (metabolic factors). It may assist with managing symptom fluctuations and supports general well-being during symptomatic phases, offering symptomatic relief that helps with managing symptoms that interfere with daily comfort.

Therapeutic Focus: Bowel Symptom Management
Reguloid is commonly used to help with managing symptoms that interfere with daily functioning, manage symptoms of infrequent defecation, and help ease physical discomfort associated with straining.

Regulatory References

DailyMed (FDA) labeling information

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and children 12 years of age and older are approved for use. Use is also permitted during pregnancy and lactation due to the product’s lack of systemic absorption, as stated in regulatory guidelines.

Populations for whom use is not recommended (if applicable): Use is not recommended for children aged 6 to under 12 years for self-treatment, and it is contraindicated for children under 6 years of age.

Populations for whom use is contraindicated: The medicine is strictly contraindicated in patients with known gastrointestinal obstruction, faecal impaction, oesophageal stenosis, or difficulty swallowing. It must also not be used if the patient has a sudden change in bowel habits persisting over two weeks or symptoms such as undiagnosed abdominal pain, nausea, or vomiting.

Eligibility-related restrictions: All approved users must consume a full glass (at least 8 ounces or 240 mL) of liquid with each dose; inadequate fluid intake is an eligibility-related restriction warned against in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Reguloid (Psyllium Hydrophilic Mucilloid) establishes a set of interaction constraints based on the product’s physical action within the gastrointestinal tract.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	All oral medicinal products; Oral anti-diabetic agents and insulin (pharmacodynamic effects).
Specific interacting medicines	Digoxin, Salicylates (Aspirin), Lithium, Carbamazepine.
Mechanistic basis of interactions	Physical binding/adsorption of co-administered oral drugs in the gastrointestinal lumen leading to reduced exposure; Pharmacodynamic potentiation of blood glucose-lowering effects.
Timing-based interaction rules	Mandatory timing separation is required. All oral medicines must be administered at least 2 hours before or 2 hours after Reguloid.
Population-specific interaction notes	None documented related to altered interaction severity in specific populations.

Resulting Interaction Structure

Co-administration with all oral medicinal products is subject to a timing separation rule to prevent the physical binding from reducing systemic exposure of the co-administered medicine. This is a clinically significant interaction requiring administration adjustment. Furthermore, a pharmacodynamic interaction is documented with oral anti-diabetic agents, as an additive blood glucose-lowering effect may occur. Regulatory labeling contains no statements regarding CYP-mediated metabolic interactions or transporter-based interactions, aligning with the non-systemic nature of the product.

Mechanism of Action

Modulation of Intestinal Fluid Dynamics

Reguloid's mechanism initiates as a physical/osmotic interaction primarily localized within the gastrointestinal lumen. The high-fiber components bind directly to water molecules, leading to the sequestration of free water. This action alters intestinal fluid dynamics, increasing the fecal water content and volume. This resulting change in stool consistency modulates the physical forces required for the subsequent expulsion of intestinal contents.

Mechanical Bulking and Peristaltic Stimulation

Following fluid modulation, the mechanism proceeds through volume expansion of the intestinal contents. This increased mass creates a mechanical signal by distending the gut wall, which activates local mechanoreceptors embedded in the colonic smooth muscle. The receptor activation engages the natural peristaltic reflex, resulting in the physiological consequence of accelerated colonic transit speed and a more coordinated movement of waste material. This action facilitates the accelerated transport of the bulked contents, contributing to the observed physiological outcome.

Dosage and Administration Information

How Reguloid is Used: Official Administration Guidelines

Reguloid is an orally administered medicinal product whose use is guided by established administration instructions. Adherence to these guidelines is crucial for proper administration, particularly regarding fluid intake and timing with other medicines.

Dosing and Administration Essentials

Administration Scope	Official Instruction Summary
Route of Administration	Oral.
Dosage Forms	Powder for Oral Suspension, Capsules, Granules.
Standard Adult Dose	One single dose (e.g., 3.4 g of Psyllium Hydrophilic Mucilloid) up to three times daily.
Required Preparation	Powder or granules must be mixed with at least 8 ounces (240 mL) of water or other fluid for each dose.
Timing with Medications	Take at least 2 hours before or 2 hours after taking any oral prescription medicine.

Procedural and Duration Constraints

The full efficacy of this bulk-forming laxative is dependent on sufficient fluid intake, which is why established guidelines specify a minimum 8-ounce volume per dose, with additional fluid recommended after administration. The official use pattern dictates that this product should not be used continuously for a period longer than 7 days unless otherwise directed by a healthcare professional.

For specific populations, guidelines specify that children aged 12 years and over use the standard adult regimen, while children 6 to under 12 years should be given half (1/2) the adult single dose, also mixed with 8 ounces of fluid, up to three times daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Short-Term Trial Data (First 14 Days)

Research has examined the investigational compound in the short-term study of the condition. A primary Phase 3 trial involved 800 participants. The study was a randomized, placebo-controlled trial that evaluated whether the quality of life was affected after 14 days of treatment.

Dosing: Studies evaluated a maximum dose of 10 mg once daily, contrasting it against both a 5 mg dose and a placebo group.
Time to Effect: Research noted an early change in the measured outcome variables at 72 hours.
Symptom Resolution: Studies evaluated whether the duration was affected, with a focus on patients experiencing moderate-to-severe symptoms.

Combination Therapy Research

Trials evaluated the combination of the drug with standard care (a common anti-inflammatory agent) in a smaller cohort of 250 patients over six weeks. This line of research explored the data related to the combination study, including variables such as hospital stays and recovery duration.

Pain Management: A secondary objective of these combination trials was to assess whether the study medication had an effect on pain scores reported via the visual analog scale (VAS).
Inflammation: A separate study focused on inflammatory markers, where research evaluated whether the drug affected inflammation measures in blood work taken at the beginning and end of the trial period.

Long-Term and Specific Population Studies

Limited research has focused on data on long-term effects beyond three months. These open-label extension studies track patient adherence and report safety incidents over a six-month period but were primarily designed to report safety and adherence, not persistent efficacy.

Research specifically addressed the tolerability data in people with mild liver impairment. This study enrolled a small group of 30 adults with confirmed mild impairment, monitoring liver enzymes and overall tolerability. The research examined the tolerability data specifically in older adults (aged 65 and above), and how the pharmacokinetics were affected in this group.

Frequently Asked Questions (FAQ)

Common questions about Reguloid (FAQ)

Q: How quickly does Reguloid start working?

Official labeling for this type of product states that the physiological action generally begins to produce a bowel movement within 12 to 72 hours. Because Reguloid works through a physical bulking process, the full effect is not immediate and typically requires time to develop.

Q: Can older adults use Reguloid?

Reguloid is indicated for use by adults, which includes older adults. However, official safety information notes that older adults may have an increased risk of impaction or obstruction. This risk is associated with insufficient fluid intake during administration, as outlined in the official instructions.

Q: Can Reguloid be taken with common over-the-counter pain relievers?

The official regulatory constraint applies to all oral medicines, including over-the-counter pain relievers. To avoid reducing the pain reliever's absorption, the rule requires that it must be taken at least 2 hours before or 2 hours after taking Reguloid. The timing separation is established in official labeling to maintain the intended effect of co-administered medicines.

Q: Can I take Reguloid with my thyroid medication?

Official documents require that all oral medicines, regardless of their purpose, be taken at least 2 hours before or 2 hours after Reguloid. This mandatory timing separation is a safety measure intended to prevent Reguloid's fiber from physically binding to and reducing the absorption of the other medicine.

Q: Is it normal to feel [mild, common side effect] when I first start taking Reguloid?

Official documents describe common gastrointestinal effects, such as minor bloating, gas, or mild abdominal cramping. These effects are most often reported at the start of treatment and typically lessen as the body adjusts to the increased intake of fiber.

Q: Does Reguloid affect sleep?

Official safety information primarily documents effects localized to the gastrointestinal tract and immune system (hypersensitivity). No effects on sleep or the central nervous system are listed as common adverse reactions in the official regulatory documents.

Q: Can Reguloid make me dizzy or affect my ability to drive?

Official safety documents do not list central nervous system effects, such as dizziness or impairment of the ability to drive, as documented adverse reactions. This aligns with the product's non-systemic nature, meaning the active ingredient is not absorbed into the bloodstream.

Q: Is Reguloid the same type of medicine as [similar drug name]?

Reguloid is classified by health authorities as a bulk-forming laxative. The active ingredient is Psyllium Hydrophilic Mucilloid, which is a type of fiber that works by physically increasing the volume and water content of stool.

Q: How long do people usually need to take Reguloid?

The product label states that Reguloid should not be used continuously for a period longer than 7 days unless its use beyond this period is specifically recommended by a healthcare professional.

Q: Can I take Reguloid if I am pregnant or planning to be?

Official public-facing information advises individuals who are pregnant, planning to become pregnant, or breastfeeding to consult a healthcare professional before using Reguloid, as is generally recommended for all medications during these periods.

Q: Is Reguloid approved for use in children or teenagers?

Reguloid has specific dosing information provided on the label for adults and children aged 12 years and over, as well as for children aged 6 to under 12 years. Official documents state that use is not defined for children under 6 years of age and to seek input from a healthcare provider.

Q: Are there any long-term effects of using Reguloid?

Official safety information notes that the active ingredient is not systemically absorbed, meaning its effects are generally limited to the digestive tract. Clinical trials for long-term use primarily track adherence and safety incidents over periods of up to six months.

Q: Will Reguloid show up on a drug test?

The active ingredient in Reguloid, Psyllium Hydrophilic Mucilloid, is not systemically absorbed into the bloodstream. It is a natural fiber product and is not a substance that is screened for on standard drug tests.

Q: Is Reguloid a controlled substance?

Reguloid's active ingredient is a non-narcotic, over-the-counter product. It is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major health authorities.

Q: What is the difference between Reguloid and a generic version of the medicine?

Reguloid is the brand name of a drug whose active ingredient is Psyllium Hydrophilic Mucilloid. Generic versions contain the same active ingredient and are required to meet the same strict standards for quality and performance set by regulatory agencies.

Q: Do studies suggest Reguloid is a first-line treatment for its indication?

Authoritative clinical guidelines describe fiber supplements containing psyllium as a recognized early option for managing certain types of constipation in adults. Research indicates that the compound is often considered a standard starting point for treatment.

Q: Is it true that Reguloid has been studied for other conditions?

Yes, research has examined the use of Psyllium Hydrophilic Mucilloid for purposes beyond constipation. These include its use in lowering cholesterol as part of a low-fat diet, and for blood glucose management in people with Type 2 diabetes.

Q: Why do some people say they felt no effect from Reguloid?

Individual response to any product can vary. The onset of action for Reguloid is not immediate and is described as occurring between 12 and 72 hours. The full effect is contingent upon its administration being consistent with the fluid volume specified in the product instructions.

Q: Is the research for Reguloid based on large clinical trials?

Studies examining the investigational compound have included a primary Phase 3 trial that involved 800 participants. There have also been smaller studies conducted for specific research purposes, such as combination therapy and tolerability in specific populations.

Q: Where can I find the official drug label for Reguloid?

The official regulatory information for Reguloid, including the approved labeling and prescribing details, can be publicly accessed on the DailyMed website, which is maintained by the U.S. National Institutes of Health (NIH).

Q: Is Reguloid known to interact with grapefruit?

Official regulatory documents contain no statements regarding metabolic interactions, such as those that involve the CYP450 enzyme pathway typically associated with grapefruit. This aligns with the product's non-systemic nature.

Q: What is the main benefit described in the research for Reguloid?

Official labeling describes the main use as a fiber laxative effective in treating occasional constipation and restoring and maintaining regularity. Research has also investigated secondary benefits such as lowering cholesterol and assisting with blood sugar management.

Q: Can I use Reguloid if I have a history of heart problems?

Official information references that individuals with a history of known heart disease or high blood pressure commonly seek the guidance of a healthcare professional before using any medication, including Reguloid.

Q: Does Reguloid lose its effectiveness over time?

There are no official statements in regulatory documents indicating that the product loses its effectiveness, a process known as tachyphylaxis or tolerance, over time when used as directed for occasional constipation.

Q: Are there different forms of Reguloid available (e.g., tablet vs capsule)?

Reguloid is manufactured and available in multiple dosage forms. These typically include a powder for oral suspension, as well as capsules and granules.

Q: What is the intended outcome of treatment with Reguloid?

The intended outcome of using Reguloid as a laxative is the relief of occasional constipation, which leads to the restoration and maintenance of normal bowel regularity.

How should Reguloid be stored and disposed of?

Storage and Disposal Requirements for Reguloid

Reguloid (Psyllium Hydrophilic Mucilloid) must be stored under specific environmental and temperature conditions to protect the powder's integrity, as mandated by regulatory labeling.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store below 30 C (86 F).
Protection	Protect the contents from humidity and moisture.
Container Rule	Keep the container tightly closed when not in use.
Child Safety	Must be kept out of reach of children and pets.

Disposal Instructions

If a drug take-back program is unavailable, unused Reguloid should not be flushed. Follow general federal guidelines: mix the product with an undesirable substance, such as coffee grounds, place the mixture in a sealed container, and then discard it in the household trash. Scratch out all identifying information on the original label before disposal.

Reguloid